Skip to main content
. 2021 Dec;379(3):343–357. doi: 10.1124/jpet.121.000845

Fig. 7.

Fig. 7.

The effect of a pharmacological inhibitor of efflux transport, elacridar, on the plasma and brain concentration of berzosertib. (A) Concentrations in plasma and brain at 2 and 8 hours postdose with and without coadministration of elacridar. (B) Brain-to-plasma ratio at 2 and 8 hours postdose with and without coadministration of elacridar. Data are presented as mean ± S.D., and n = 5 for each group. **P < 0.01 and ***P < 0.005.